Eli Lilly and Company $LLY Shares Acquired by Alpha Cubed Investments LLC

Alpha Cubed Investments LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,852 shares of the company’s stock after purchasing an additional 912 shares during the period. Alpha Cubed Investments LLC’s holdings in Eli Lilly and Company were worth $11,578,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the period. Covestor Ltd grew its position in shares of Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after buying an additional 85 shares during the last quarter. Kaufman Rossin Wealth LLC acquired a new stake in Eli Lilly and Company during the first quarter worth about $242,000. Finally, Opes Wealth Management LLC lifted its holdings in Eli Lilly and Company by 6.6% in the first quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock worth $278,000 after acquiring an additional 21 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on LLY. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, November 3rd. Finally, Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $960.88.

Eli Lilly and Company Stock Performance

LLY opened at $923.35 on Monday. The company has a market cap of $872.92 billion, a PE ratio of 60.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The stock has a 50-day moving average of $799.97 and a 200-day moving average of $775.01. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $955.46. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the business earned $1.18 EPS. The firm’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 4,314 shares of company stock valued at $2,766,929 in the last quarter. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.